Institutional members access full text with Ovid®

Share this article on:

Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy

Blümer, Regje MEa; van Vonderen, Marit GAb,d; Sutinen, Jussif,g; Hassink, Ellye; Ackermans, Mariettec; van Agtmael, Michiel Ad; Yki-Jarvinen, Hannelef; Danner, Sven Ad; Reiss, Peterb,e; Sauerwein, Hans Pa

doi: 10.1097/QAD.0b013e3282f33557
Clinical Science

Background: Patients with antiretroviral therapy (ART)-associated lipodystrophy frequently have disturbances in glucose metabolism associated with insulin resistance. It is not known whether changes in body composition are necessary for the development of these disturbances in ART-naive patients starting treatment with different combination ART regimens.

Methods: Glucose metabolism and body composition were assessed before and after 3 months of ART in a prospective randomized clinical trial of HIV-1-positive ART-naive men taking lopinavir/ritonavir within either a nucleoside reverse transcriptase inhibitor (NRTI)-containing regimen (zidovudine/lamivudine; n = 11) or a NRTI-sparing regimen (nevirapine; n = 9). Glucose disposal, glucose production and lipolysis were measured after an overnight fast and during a hyperinsulinaemic–euglycaemic clamp using stable isotopes. Body composition was assessed by computed tomography and dual-energy X-ray absorptiometry.

Results: In the NRTI-containing group, body composition did not change significantly in 3 months; insulin-mediated glucose disposal decreased significantly (25%; P < 0.001); and fasting glycerol turnover increased (22%; P < 0.005). Hyperinsulinaemia suppressed glycerol turnover equally before and after treatment. The disturbances in glucose metabolism were not accompanied by changes in adiponectin or other glucoregulatory hormones. In contrast, glucose metabolism did not change in the NRTI-sparing arm. Glucose disposal significantly differed over time between the arms (P < 0.01).

Conclusions: Treatment for 3 months with a NRTI-containing, but not a NRTI-sparing, regimen resulted in a 25% decrease in insulin-mediated glucose disposal and a 22% increase in fasting lipolysis. In the absence of discernable changes in body composition, NRTI may directly affect glucose metabolism, the mechanism by which remains to be elucidated.

From the aDepartment of Endocrinology and Metabolism, the Netherlands

bDepartment of Infectious Diseases, Tropical Medicine and AIDS (Center for Infection and Immunity Amsterdam), the Netherlands

cDepartment of Clinical Chemistry, Laboratory of Endocrinology and Radiochemistry, Academic Medical Center, the Netherlands

dDepartment of General Internal Medicine, VU University Medical Center, the Netherlands

eInternational Antiviral Therapy Evaluation Center, Amsterdam, the Netherlands

fDivision of Diabetes, Helsinki University Central Hospital, Helsinki, Finland

gDivision of Infectious Diseases, Helsinki University Central Hospital, Helsinki, Finland.

Received 21 April, 2007

Revised 30 September, 2007

Accepted 9 October, 2007

Correspondence to Dr R. Blümer, Department of Endocrinology and Metabolism, Academic Medical Center, PO Box 22660, 1100 DD Amsterdam, the Netherlands. E-mail: r.blumer@amc.uva.nl

© 2008 Lippincott Williams & Wilkins, Inc.